Clinical trials: Advanced Solid Cancer
Cancer, Tumor
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
This is a study evaluating the safety and effectiveness of Combretastatin A4 Phosphate (CA4P) combined with the chemotherapy drugs, carboplatin and paclitaxel. The full treatment and observation time should be about 5 months.
- Trial name
- NCT00113438
- Testing
- Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mateon Therapeutics
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Advanced Solid Tumors
Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.
- Trial name
- NCT00734305
- Testing
- MM-121
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Merrimack Pharmaceuticals
Advanced Solid Tumor
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
This is a phase 1 / 2 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-15293 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2…
- Trial name
- NCT05173805
- Testing
- YL-15293
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Advanced Solid Tumor, Lung Squamous Cell Carcinoma
JMT106 Injection in the Treatment of Advanced Solid Tumors
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT07275073
- Testing
- JMT106 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Advanced Solid Tumours
A Study of EBC-129 in Advanced Solid Tumours
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
- Trial name
- NCT05701527
- Testing
- EBC-129, Pembrolizumab
- Where
- 5 sites in United States, Singapore and 1 more
- Volunteers
- 98 people
- Sponsor
- EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Solid Tumor
Safety Study of PLX108-01 in Patients With Solid Tumors
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable…
- Trial name
- NCT01004861
- Testing
- PLX3397
- Where
- 13 sites in United States
- Volunteers
- 132 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor, Advanced Lung Cancer
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
This trial is an open-label, multicenter, first-in-human dose-escalation and cohort expansion Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of IMM2902 in the treatment of HER2-expressing…
- Conditions
- Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma, Advanced Cholangiocarcinoma
- Trial name
- NCT05805956
- Testing
- IMM2902
- Where
- 2 sites in China
- Volunteers
- 105 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Advanced Solid Tumor
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy adult subjects after oral administration of HRS-1167 tablets.
- Trial name
- NCT06198556
- Testing
- HRS-1167 tablets; rifampicin
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignant Solid Tumours
A Study of RT023 in Patients With Advanced Solid Tumors
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of RT023 in Subjects with Advanced Malignant Solid Tumour.
- Trial name
- NCT07797426
- Testing
- RT023
- Volunteers
- 318 people
- Sponsor
- Shanghai Ruotuo Biosciences Co., Ltd.
Solid Tumor
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Phase 1 (dose escalation) of this study will evaluate: The safety and tolerability of EU103 treatment are evaluated for patients with advanced or metastatic solid tumors who have failed standard therapy to determine the maximum…
- Trial name
- NCT05798026
- Testing
- EU103
- Where
- 3 sites in South Korea
- Volunteers
- 15 people
- Sponsor
- Eutilex
Advanced Solid Tumors
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects with advanced solid tumors.
- Trial name
- NCT06329206
- Testing
- GH2616 Tablets
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Advance Solid Malignancies, Metastatic Solid Malignancies
A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
This is a single-centre, phase 1a (dose escalation) and 1b (dose expansion) study to evaluate the safety and tolerability of oral Selinexor in combination with nivolumab and ipilimumab in patients with advanced solid malignancies.
- Trial name
- NCT04850755
- Testing
- Selinexor in combination with nivolumab and ipilimumab
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- National University Hospital, Singapore
Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild, moderate, or severe hepatic impairment.
- Trial name
- NCT01991678
- Testing
- 145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nektar Therapeutics
Advanced Solid Tumors
Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.
- Trial name
- NCT05905614
- Testing
- SPH4336 Tablets
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumor
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors.
- Trial name
- NCT06993116
- Testing
- SHR-4712 Injection
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
This phase I trial studies the side effects and the best dose of PI3K inhibitor BKM120 when given together with cisplatin and etoposide in treating patients with advanced solid tumors or small cell lung cancer.
- Trial name
- NCT02194049
- Testing
- BKM120, cisplatin, etoposide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of California, Davis
Solid Tumor
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, dose escalation and expansion phase I /II study of IBI3004 in subjects with unresectable, locally advanced or metastatic solid tumors.
- Trial name
- NCT06198426
- Testing
- IBI3004
- Where
- 5 sites in Australia, China
- Volunteers
- 5 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.